Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Gladstone Land (LAND) to Offer 1.1M Shares of Common Stock
-
Gladstone Land (LAND) Announces 1.1M Common Stock Offering
-
Gladstone Land Corporation Announces Common Stock Offering
-
Gladstone Land Corporation Announces Common Stock Offering
-
Maxim Group Starts REEDS, Inc. (REED) at Buy
-
Aeterna Zentaris (AEZS) Prices Common Share/Warrant Offering at $5.55
-
Aeterna Zentaris Announces Pricing of US$16.65 Million Public Offering of Common Shares and Warrants
-
Workhorse Group Completes Private Placement of $13.5 Million in Convertible Notes With Warrants
-
Maxim Group Starts Cracker Barrel (CBRL) at Buy
-
Aeterna Zentaris (AEZS) to Offer Common Stock and Warrants
-
Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants
-
Norovirus suspected at Chipotle visited by 80 sick Boston College students
-
Maxim Group's Jason Kolbert and Jason McCarthy Interviewed by The Life Sciences Report
-
Maxim Group's Jason Kolbert and Jason McCarthy Interviewed by The Life Sciences Report
-
Prospect Capital Corporation Prices Public Offering of $150 Million of 6.25% Unsecured Notes Due 2024
-
Unusual 11 Mid-Day Movers 12/2: (ONDK) (MTSN) (ADMP) Higher; (ZFGN) (OGXI) (ATV) Lower
-
Anavex Life Sciences (AVXL) Latest Hire Seen as Important - Maxim Group
-
Cesca Therapeutics (KOOL) Has It All But Cash; Reiterated 'Buy' - Maxim Group
-
Kite Pharma (KITE) Bullish View Reiterated at Maxim Group Following Third Registraion Trial
-
ImmunoCellular (IMUC) Bullish View Reiterated at Maxim Group Amid ICT-107 Agreement
-
Celyad (CYAD) Bullish Stance Reiterated at Maxim Group as First Patient of Second Cohort Infused
-
Maxim Group Starts Adamis Pharmaceuticals (ADMP) at Buy
-
Maxim Group Positive on Anavex Life Sciences (AVXL) After Data Published in Respected Journal
-
The Joint Corp. (JYNT) Completes 2.27M Common Stock Follow-on Offering
-
The Joint Corp. Announces Closing of Follow-On Public Offering of Common Stock
-
The Joint Corp. Announces Closing of Follow-On Public Offering of Common Stock
-
Applied DNA Sciences (APDN) Closes 2.5M Share Registered Direct Offering
-
Applied DNA Sciences Announces Closing of $8.75 Million Registered Direct Offering
-
Maxim Group Reiterates Bullish View on Opexa Therapeutics (OPXA)
-
Notable Analyst Rating Changes 11/24: (EMES) (AVP) (QCOM) Upgraded; (GME) (BLOX) (ARP) Downgraded
-
UPDATE: Maxim Group Starts Stellar Biotechnologies (SBOT) at Buy
-
Maxim Group Starts Granite Construction (GVA) at Buy
-
Maxim Group Starts COPsync (COYN) at Buy
-
Notable Analyst Rating Changes 11/23: (CMG) (JRVR) (PBF) Upgraded; (TXTR) (CTCT) (CAVM) Downgraded
-
Applied DNA Sciences Announces $8.75 Million Registered Direct Offering
-
Applied DNA Sciences (APDN) Enters Common Stock, Warrants Direct Placement
-
Maxim Group Upgrades Hewlett-Packard (HPQ) to Buy
-
Maxim Group Upgrades Panera Bread (PNRA) to Buy
-
Maxim Group Starts HP Enterprise (HPE) at Hold
-
Viveve Announces $6 Million Private Placement of Common Stock Led by Leading Healthcare-Focused Institutional Investors
-
Emmaus Life Sciences to Present at Maxim Group's Sickle Cell Disease Investor Conference on November 20
-
The Joint Corp. (JYNT) Prices 2.27M Common Follow-on Offering at $5.50/Share
-
The Joint Corp. Prices Follow-On Public Offering of Common Stock
-
The Joint Corp. Prices Follow-On Public Offering of Common Stock
-
PLx Pharma (PLXP) Lifts IPO Registration Price
-
COPsync Announces Closing of $10.6 Million Underwritten Offering
-
COPsync Announces Closing of $10.6 Million Underwritten Offering
-
StemCells (STEM) to Report 6-Month Interim Results at 4:30PM ET- Analyst
-
Maxim Group Downgrades Oxford Lane (OXLC) to Hold
-
Radius Health (RDUS) Delay in U.S. 'Bad News', Maxim Group Says

